US FDA clears troubled API plants following two Form 483s, says Dr. Reddy’s

By Flora Southey

- Last updated on GMT

Getty/Blablo101
Getty/Blablo101
Dr. Reddy’s Laboratories has announced receipt of a US FDA establishment inspection report regarding two active pharmaceutical ingredient plants in Hyderabad, India.

On March 9, 2018, the US Food and Drug Administration (FDA) issued Dr. Reddy’s a Form 483​ with five observations after an inspection of its Bollaram facility in the Indian state of Telengana earlier that month.

One week later, the firm announced receipt​ of an FDA Form 483 with four observations​, following a regulatory inspection of its active pharmaceutical ingredient (API) Plant 1 in Jinneram Mandal, Telangana.

In a Bombay Stock Exchange filing issued last week, the firm stated it had “received an establishment inspection report from the US FDA, for both of the above-referred facilities.”

“The establishment inspection report (EIR) indicates clearance from the US FDA for both these sites,” ​a Dr. Reddy’s spokesperson told us, adding that “no further actions” ​are required.

The regulatory nod follows recent drug manufacturing and commercialisation issues for the India-headquartered firm. Last week​, Indivior sought an injunction against Dr. Reddy’s to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.

And yesterday​, we reported impurity issues had prompted Dr. Reddy’s to voluntarily recall more than 236,000 bottles of statins made at its troubled Srikakulam facility​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars